HOME >> BIOLOGY >> NEWS
Introgen publishes preclinical findings demonstrating the potent anti-tumor properties of INGN 241 study featured on the cover of Molecular Medicine

Austin, TX, May 10, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today the publication of its preclinical studies in the current issue of Molecular Medicine demonstrating the potent anti-tumor effects of INGN 241 (an adenoviral vector encoding the mda-7 gene) in three of the most prevalent human cancers, breast, lung and colorectal.

The study also demonstrates, for the first time, that MDA-7 protein is released from cancer cells treated with Adenoviral-mda7. The lead author of the publication is Abner Mhashilkar, Ph.D., project leader of Introgens mda-7 program. The cover of Molecular Medicine featured a photomicrograph which demonstrates secretion of MDA-7 protein from INGN 241 treated cells, a result which may enhance the potency of INGN 241 therapy.

The research and paper are the result of the efforts of an international team of collaborators, including scientists from The University of Texas M. D. Anderson Cancer Center, the Imperial Cancer Research Technology in the United Kingdom, Corixa Corporation and Columbia University College of Physicians and Surgeons. The study was funded in part by grant R43 CA86587 from the National Cancer Institute.

We have previously shown that INGN 241 will selectively kill lung tumor cells by inducing the cells to commit suicide, a process known as apoptosis, said Sunil Chada, Ph.D., Introgens director of research and development and senior author of the manuscript. These new functional studies indicate that the mda-7 gene has tumor suppressor activity in some of the most prevalent human cancers. Introgens research also demonstrates that the MDA-7 protein is secreted. These unique properties of INGN 241 suggest that it may be a potent anti-tumor agent for local-regional applications, and potentially for the systemic treatment of cancer.

The studies involved functional biological assays coupled with genomic analytic tools. These studies indicated that INGN 241 suppressed growth in 19 out of
'"/>

Contact: Andi Wakayama
a.wakayama@noonanrusso.com
415-677-4455 ext 252
Noonan/Russo Communications
9-Apr-2001


Page: 1 2 3 4

Related biology news :

1. Introgens gene drug demonstrates tumor growth control
2. New family of 10 cancer related genes discovered by NCI, University of Texas and M.D. Anderson researchers; licensed by Introgen
3. Introgen Therapeutics reports advances in RPR/INGN 201 clinical program for treatment of advanced cancers
4. Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting
5. Wiley publishes Welcome to the Genome: A Users Guide to the Genetic Past, Present, and Future
6. Warren Pharmaceuticals publishes results of preclinical evaluation
7. Professor publishes book on historic mosquito wars
8. AGI publishes 42nd edition of Directory of Geoscience Departments
9. International HapMap Consortium publishes scientific strategy
10. Ingenium publishes biological characterization of first mouse model for kidney stones
11. OHSU researcher publishes first measurements of free-base nicotine in cigarette smoke

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/8/2019)... , ... May 08, 2019 , ... ... with a diameter of 200 microns and a lead-in fiber of 100 microns. ... new industry standard and positioning itself as the world leader in the development ...
(Date:5/2/2019)... (PRWEB) , ... April 30, 2019 , ... ... Nadel LLP is pleased to announce that Gunes Bender, Ph.D., a registered ... life sciences practice group. In his new role, Bender provides technical support and ...
(Date:5/2/2019)... ... 2019 , ... uBiome, the leader in microbial genomics, today ... Counsel, as Interim Chief Executive Officer of uBiome, effective immediately. The Company’s Co-CEOs ... will also be an independent investigation into uBiome’s billing practices to be overseen ...
Breaking Biology News(10 mins):
(Date:4/18/2019)... WORCESTER, Mass. (PRWEB) , ... April 18, 2019 ... ... for fossil fuels, a research team that includes a chemical engineer at Worcester ... an exotic microorganism that may make it possible to manufacture isobutanol and other ...
(Date:4/10/2019)... ... April 10, 2019 , ... RoosterBio ... multiple agreements to help companies advance their innovations to clinical testing more ... synthetic biology companies that are gene editing therapeutic cells for advanced functionality ...
(Date:4/8/2019)... ... April 08, 2019 , ... ... solutions, announced today the launch of their app integration solution, CT Cloud Unite. ... and contact-orientated applications while using CT Cloud Voice and Skype for Business solutions. ...
(Date:3/29/2019)... , ... March 28, 2019 , ... ... and testing milestones, CARB-X has proceeded with a second stage of funding for ... $1.7 million, which is on top of the $1.7 million already awarded by ...
Breaking Biology Technology:
Cached News: